Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1645689

	registered interest
	date	19/06/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Clinical Trials
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure the Medicines and Healthcare products Regulatory Agency meets its statutory obligation to assess clinical trials within 60 days of notification.
	tabling member constituency	Bethnal Green and Bow
	tabling member printed	Rushanara Ali
	uin	190132
	answer	answer is ministerial correction date of answer 26/06/2023 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is committed to making regulatory decisions in accordance with statutory timeframes. The MHRA has recently undertaken a significant recruitment exercise to bring on board new specialist staff to increase clinical trial assessor capacity within the Agency. The MHRA are supplementing this new assessor capacity with additional fixed-term resource of appropriately experienced and qualified specialists to support the training and supervision of new staff.</p><p>The MHRA continue to develop plans to increase staff capability and expertise, and to review internal processes for efficiencies. To that end, significant progress has been made to draft proposals for how a risk-proportionate approach to clinical trial assessments could be implemented.</p><p>Following public consultation, the MHRA plans to reform national legislation to deliver a world-class sovereign regulatory environment for clinical trials that will support the development of innovative medicines and ensure that the UK retains and grows its reputation as a world leading base for life sciences.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 190133 question first answered 26/06/2023 15:01:18 answering member 4423 label Biography information for Will Quince
	tabling member	4138 label Biography information for Rushanara Ali

1645690

	registered interest
	date	19/06/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Clinical Trials
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the time taken to conduct clinical trial approvals by the Medicines and Healthcare products Regulatory Agency on the UK's life sciences sector.
	tabling member constituency	Bethnal Green and Bow
	tabling member printed	Rushanara Ali
	uin	190133
	answer	answer is ministerial correction date of answer 26/06/2023 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is committed to making regulatory decisions in accordance with statutory timeframes. The MHRA has recently undertaken a significant recruitment exercise to bring on board new specialist staff to increase clinical trial assessor capacity within the Agency. The MHRA are supplementing this new assessor capacity with additional fixed-term resource of appropriately experienced and qualified specialists to support the training and supervision of new staff.</p><p>The MHRA continue to develop plans to increase staff capability and expertise, and to review internal processes for efficiencies. To that end, significant progress has been made to draft proposals for how a risk-proportionate approach to clinical trial assessments could be implemented.</p><p>Following public consultation, the MHRA plans to reform national legislation to deliver a world-class sovereign regulatory environment for clinical trials that will support the development of innovative medicines and ensure that the UK retains and grows its reputation as a world leading base for life sciences.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 190132 question first answered 26/06/2023 15:01:18 answering member 4423 label Biography information for Will Quince
	tabling member	4138 label Biography information for Rushanara Ali

1645691

	registered interest
	date	19/06/2023
	answering body	Department for Environment, Food and Rural Affairs
	answering dept id	13
	answering dept short name	Environment, Food and Rural Affairs
	answering dept sort name	Environment, Food and Rural Affairs
	hansard heading	Inland Waterways: Biodiversity
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Environment, Food and Rural Affairs, what steps she is taking to conserve biodiversity in canals.
	tabling member constituency	Bethnal Green and Bow
	tabling member printed	Rushanara Ali
	uin	190134
	answer	answer is ministerial correction date of answer 27/06/2023 answer text <p>We recognise that the inland waterways across England and Wales are an important national asset forming an important part of our natural environment by providing green and blue corridors along which biodiversity can flourish.</p><p> </p><p>We are committed to recovering nature, including restoring our freshwater habitats, which is why we have now set four legally binding targets for biodiversity. By 2030 we have committed to halt the decline in species abundance and by 2042 we aim to reverse species decline; to reduce the risk of species extinction; and to restore or create more than 500,000 hectares of wildlife-rich habitats. Action towards these targets will drive essential improvements to our freshwater habitats.</p><p> </p><p>Defra is committed to improve at least 75% of our waters to as ‘close to their natural state’ as soon as is practicable, set out in the EIP. In April we published our Integrated Plan for Delivering Clean and Plentiful Water. The actions in the plan aim to restore all types surface waters, for example, river, lakes and canals.</p> answering member constituency Copeland answering member printed Trudy Harrison question first answered 27/06/2023 08:44:06 answering member 4593 label Biography information for Trudy Harrison
	tabling member	4138 label Biography information for Rushanara Ali